Work

Phase II trial of CV301 vaccine combined with atezolizumab in advanced urothelial carcinoma

Year: 2022

Type: article

Study design: Clinical Trial

Source: Cancer Immunology Immunotherapy

DOI: 10.1007/s00262-022-03274-6

Authors: Guru P. Sonpavde, Benjamin Louis Maughan, Bradley Alexander McGregor, Xiao X. Wei, Kerry L. Kilbridge, Richard J. Lee, Evan Y. Yu, Michael Thomas Schweizer, Robert B. Montgomery, Heather H. Cheng, Andrew Caleb Hsieh, Rohit Jain, Jaspreet S. Grewal, Cesar Pico-Navarro, Zarina Gafoor, Teresa Perschy, Petros Grivas

Institutions: Harvard University, Dana-Farber Cancer Institute, Dana-Farber/Harvard Cancer Center, University of Utah, Massachusetts General Hospital, University of Washington, Fred Hutch Cancer Center, Moffitt Cancer Center, Norton Healthcare, Bavarian Nordic (United States)

Language: English

Topic: Bladder and Urothelial Cancer Treatments

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funder: Bavarian Nordic

OpenAlex ID: W4292835116

FWCI: 2.324

Cites: 20

Cited by: 15

Related to: 10